Market viability is decided before the first order.
Prythos connects demand, regulatory pathway, product fit and importer signals, so pharma exporters judge which market is worth the registration effort, and which importer to approach, before the effort is spent.
In pharma, entering a market is not the same as selling into it. A product is typically registered or authorised before it can be sold; the facility that makes it is often registered or inspected; and the party who imports it usually needs to be licensed. The order comes late in a long chain of approvals.
That makes every market a commitment. Time and money go into the file before a single batch ships, so the cost of picking the wrong market is paid up front.
The United States alone took about 31% of exports in April–June 2026; Brazil, the United Kingdom, the Netherlands and France followed (Indian Pharma Post, 12 Aug 2026). `` secondary report of Pharmexcil data; check Pharmexcil or DGCI&S before publishing.
A market can be large and still wrong for your product.
The biggest market takes about 31% of exports; the rest is spread across destinations with different rules, different registered competitors and different importers. Size is the easiest signal to see and the weakest signal to decide on.
What decides viability sits underneath: whether your product can be registered there, whether it fits what the market already registers and buys, whether a licensed importer will carry it, and whether the cost and time of entry are justified by the likely volume.
One viability decision. Six layers of signal.
Market demand.
Where is there demand for this molecule, strength and form, and who already supplies it?
Regulatory pathway.
In the US, foreign establishments whose drugs are imported must register with FDA and identify a US agent physically located in the US (FDA, content current as of 2 Jan 2016; FDA CDER workshop slides, 12 Sep 2024). In the EU, importing medicinal products from third countries requires authorisation, and the Directive provides for quality controls on third-country batches in the importing Member State unless suitable arrangements exist (Directive 2001/83/EC, Arts. 40 and 51, original text). ``
Product fit.
Does your strength, form and pack match what the market registers and buys?
Importers.
Which licensed importers and distributors carry this therapeutic area, and are they active?
Trade terms.
The India-UK CETA entered into force on 15 July 2026 (PIB, 17 Jun 2026); the India-EU FTA was concluded on 27 January 2026 and is not yet in force (India Briefing, updated 22 Oct 2026). Treatment of pharmaceutical tariff lines must be checked individually. US tariff treatment is unsettled.
Viability.
Given entry effort, expected volume and competition, is it worth it?
- Input 01: DEMAND converges into DECISION
- Input 02: REGS converges into DECISION
- Input 03: FIT converges into DECISION
- Input 04: IMPORTER converges into DECISION
- Input 05: TERMS converges into DECISION
- Input 06: COST converges into DECISION
Reports, consultants and calls.
A market report from last year. A regulatory consultant engaged for one country at a time. A call to a contact who knows a distributor. A spreadsheet of registered competitors. Each is valuable; the picture they form only exists in the exporter's head.
The risk: effort committed to a registration before the market's viability is understood end to end.
Prythos shows whether a market is worth the file.
Prythos is the intelligence layer between scattered trade and regulatory signals and the decision in front of you. It reads demand, regulatory environment, product fit and importer activity together, and returns an answer to a commercial question: which markets are worth the registration effort.
Don't give your team more data. Give them a better decision.
Prythos supports commercial decisions. It does not provide regulatory or legal advice, and it does not replace regulatory affairs expertise.
`` Capability language describes the product as designed. Confirm each signal source is live at launch and trim any line that is not.
Five decisions every pharma exporter faces.
| Decision | The question you are really asking | What Prythos brings together |
|---|---|---|
| Where the demand is | Which markets want this product, and who supplies it today? | Destination demand, trade flows and competing suppliers |
| What entry requires | What must be registered, and by whom? | Registration pathway and facility requirements mapped to your product |
| Whether it fits | Does my strength, form and pack match what the market buys? | Product-to-market fit signals |
| Who will carry it | Which licensed importers handle this therapeutic area? | Importer and distributor profiles ranked by fit and activity |
| Whether it is worth it | Does expected volume justify the cost and time of entry? | A viability view: effort, demand and competition together |
From demand to a market worth the dossier.
Where is there demand for this product and format?
Signals: demand, competing suppliers, price levels
What must be registered, and by whom?
Signals: registration pathway, facility rules, local agent
Does your product fit what this market registers and buys?
Signals: molecule, strength, form, pack
Which licensed importers handle it, and are they active?
Signals: importers, distributors, portfolio
Does the market justify the cost and time of entry?
Signals: entry effort, expected volume, competition
Which market and importer are worth the dossier?
Signals: a prioritised shortlist, with the reasons
- Step 1: Demand. Where is there demand for this product and format?. Signals: demand, competing suppliers, price levels.
- Step 2: Regulation. What must be registered, and by whom?. Signals: registration pathway, facility rules, local agent.
- Step 3: Product fit. Does your product fit what this market registers and buys?. Signals: molecule, strength, form, pack.
- Step 4: Importer. Which licensed importers handle it, and are they active?. Signals: importers, distributors, portfolio.
- Step 5: Viability. Does the market justify the cost and time of entry?. Signals: entry effort, expected volume, competition.
- Step 6: Opportunity. Which market and importer are worth the dossier?. Signals: a prioritised shortlist, with the reasons. (Key opportunity milestone)
Each step removes options the evidence does not support. What remains is a market and an importer worth the registration effort, with the reasons attached.
The importer is a regulated partner, not just a buyer.
| Step | What happens | What it answers |
|---|---|---|
| Find the viable market | Demand, regulation and fit narrow the world to markets worth the file | Where should I look? |
| Map the importers | Licensed importers and distributors for your therapeutic area are identified | Who can carry my product there? |
| Prioritise | Importers ranked by portfolio fit and activity, with reasoning | Who first, and why? |
Prythos prioritises. You decide. Every ranking shows its reasoning.
A viable market still needs a converted order.
- Stage 1: RFQ
- Stage 2: Qualification
- Stage 3: Quote
- Stage 4: Follow-up
- Stage 5: Outcome (Outcome learned and recorded)
The Export Revenue Agent takes an opportunity from first enquiry to recorded outcome:
Is this enquiry from a party that can actually import in that market? What should the quote say, given what is known about the market? When and how should we follow up? What did we learn from winning or losing?
`` Stage descriptions must match the Export Revenue Agent copy on the How it works page.
A mid-sized Indian generics manufacturer is weighing its first regulated-market entry.
| Step | The question | What the evidence would show | The decision |
|---|---|---|---|
| Demand | Where is there demand for our product? | Destination demand and current suppliers | A handful of candidate markets |
| Regulation | What would entry require in each? | Registration and facility requirements side by side | Drop markets whose entry effort is out of proportion |
| Fit | Does our product fit what they buy? | Strength, form and pack against the market's registered products | Confirm the product to lead with |
| Importer | Who would carry it? | Licensed importers by portfolio fit and activity | A short list to approach |
| Viability | Is it worth it? | Entry effort against expected volume and competition | A go or no-go with the reasons written down |
No number appears in this scenario because none is real. When Prythos has customer results, they replace this section.
What changes when the decision is evidence-led.
Registration effort follows viability, not enthusiasm.
Entry requirements are understood before they become a surprise.
Importers are approached on fit, not on whoever answered.
A go or no-go carries its reasons, so it can be reviewed.
Every outcome informs the next market decision.
These are the changes Prythos is designed to make. They are aims, not measured results, until customer evidence exists.
Four principles, one standard.
Evidence.
Every claim carries its source and date. If we cannot source it, we do not say it.
Intelligence.
Signals connected into a decision, not stacked into a dashboard.
Action.
The work continues through the RFQ to the outcome.
Precision.
Your product, your market, your importer. Not an industry average.
Don't give businesses more data. Give them better decisions.
Pre-launch, so the proof is the evidence behind the problem.
Prythos has no customer results to show yet, and this page will not pretend otherwise. What it can stand behind today is the evidence for the problem it is built to solve:
| Figure | Source | Period |
|---|---|---|
| Pharma exports US$ 8.10 billion, +6.80% | Indian Pharma Post, citing Pharmexcil | Apr–Jun 2026 |
| US the largest market: US$ 2.50 billion, 30.89% | Indian Pharma Post, citing Pharmexcil | Apr–Jun 2026 |
| Foreign drug establishments must register and name a US agent | FDA | Page current as of 2016 |
“I'm JImmey, the founder of Prythos. Before building it, I spent time in conversation with exporters and industry leaders, and eight months working inside the industry. What stood out was not a shortage of information. It was how much effort it took to turn scattered information into a decision someone could act on. Prythos is my answer: not more data, but better decisions, carried through to revenue.”
Decide which market is worth the file.
Export intelligence is moving from research you read to decisions you can act on. Join the waitlist to see what that looks like for your product.
Sources for this page
All pages read on 25 Oct 2026. Where a source did not state an as-of date, that is noted.
- Indian Pharma Post (IPP Bureau), 12 Aug 2026, citing Pharmexcil — indianpharmapost.com. Secondary. It states a year-earlier base of US$ 7.58 billion; 8.10 / 7.58 gives 6.9%, so the stated 6.80% reflects rounding in the inputs. No FY2025-26 full-year total is given.
- FDA, "If I am required to register my drug facility and list my drug product, how do I proceed?" — fda.gov. Content current as of 2 Jan 2016; old.
- FDA CDER, Establishment Registration Highlights, SBIA workshop, 12 Sep 2024 — fda.gov. Confirms the US agent requirement (21 CFR 207.69(b)).
- EUR-Lex, Directive 2001/83/EC, original text (OJ L 311, 28.11.2001) — eur-lex.europa.eu. Not the consolidated version.
- PIB, India-UK CETA release, 17 Jun 2026 — pib.gov.in
- India Briefing, India FTA tracker (updated 22 Oct 2026) — india-briefing.com. Secondary.